• EDAP, developer of promising medical devices for HIFU and ESWL treatments, has been buffeted by hospitals concentrating on treating Covid-19 patients.
• However, this looks like postponement to us, with little long-term damage to the company’s perspectives, which remain bright.
• We therefore see the 50%+ correction in the share price as an opportunity.

Source: (Exclusive) The Selloff In EDAP Looks Overdone (NASDAQ:EDAP) | Seeking Alpha